Effect of a new psychoactive compound, MCI-225, on brain monoamine metabolism in rats.
Effect of MCI-225 on brain monoamine metabolism was examined in rats. MCI-225 (30 mg/kg, p.o.) had no influence on noradrenaline (NA) levels, but significantly inhibited the NA turnover in the hippocampus and hypothalamus. This compound also significantly increased the 5-hydroxyindoleacetic acid (5-HIAA)/5-hydroxytryptamine ratio in the cerebral cortex, hippocampus and striatum; and it enhanced the probenecid-induced 5-HIAA accumulation in the striatum. In the microdialysis study, MCI-225 markedly increased the NA output, but decreased the 3,4-dihydroxyphenylethyleneglycol output from the hypothalamus of urethane-anesthetized rats. These results suggest that MCI-225 enhances both noradrenergic and serotonergic function by inhibiting NA uptake and accelerating 5-HT turnover, respectively.
Oishi
R
R
Department of Pharmacology, Okayama University Medical School, Japan.
Itoh
Y
Y
Adachi
N
N
Saeki
K
K
D000818:Animals; D015306:Biogenic Monoamines / Q000378:metabolism*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism*; D008297:Male; D010879:Piperazines / Q000494:pharmacology*; D011619:Psychotropic Drugs / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
D015306:Biogenic Monoamines; D010879:Piperazines; D011619:Psychotropic Drugs; D011743:Pyrimidines; C085298:MCI 225